Alshamsan Aws
Nanomedicine Research Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, 2457, Riyadh, 11451, Saudi Arabia.
King Abdullah Institute for Nanotechnology, King Saud University, 2455, Riyadh, 11451, Saudi Arabia.
Methods Mol Biol. 2017;1530:257-270. doi: 10.1007/978-1-4939-6646-2_15.
Nanotechnology offers invaluable tools to tailor cancer vaccines in order to generate robust antitumor immune response. Among the types of vehicles for cancer vaccines, nanoparticles (NPs) are easier to produce with better scalability. Several nanostructures have been discussed in literature as potential delivery systems for cancer antigens. Here, we focus on polymeric NPs fabricated from poly(D,L-lactic-co-glycolic) acid (PLGA). We describe how to prepare and characterize such NPs loaded with ovalbumin (OVA) antigen and immune adjuvant monophosphoryl lipid A (MPLA). We further describe methods to test the immune efficacy of such NPs in vitro and in vivo.
纳米技术提供了宝贵的工具来定制癌症疫苗，以产生强大的抗肿瘤免疫反应。在癌症疫苗的载体类型中，纳米颗粒（NPs）更容易生产且具有更好的可扩展性。文献中已经讨论了几种纳米结构作为癌症抗原的潜在递送系统。在这里，我们专注于由聚（D，L-乳酸-共-乙醇酸）（PLGA）制成的聚合物纳米颗粒。我们描述了如何制备和表征负载卵清蛋白（OVA）抗原和免疫佐剂单磷酰脂质A（MPLA）的此类纳米颗粒。我们还描述了在体外和体内测试此类纳米颗粒免疫效果的方法。
